Vaxcyte's pneumococcal vaccine data drives share price jump

18 April 2023
vaxcyte-large

Californian vaccine firm Vaxcyte (Nasdaq: PCVX) has announced positive results from a Phase II study of VAX-24, its broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate.

Data was also presented from the full six-month safety assessment and prespecified pooled immunogenicity analyses from both the Phase II study in adults aged 65 and older, and the prior Phase I/II study in adults aged 18 to 64.

"We look forward to meeting with regulators and advancing VAX-24 into a pivotal Phase III study"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical